Product

DSP-0509

Aliases

DSP-0509, Pembrolizumab

1 clinical trial

1 indication

Indication

Clinical trial

A First-in-Human Phase 1/2 Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, Administered as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Status: Completed, Estimated PCD: 2022-12-20